Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

Cullinan Therapeutics (CGEM) Non-cash Items (2021 - 2022)

Cullinan Therapeutics has reported Non-cash Items over the past 2 years, most recently at $66.0 million for Q4 2022.

Quarterly results put Non-cash Items at $66.0 million for Q4 2022, down 12.93% from a year ago — trailing twelve months through Dec 2022 was $66.0 million (down 12.93% YoY), and the annual figure for FY2022 was $3.7 million, down 95.11%.
Non-cash Items for Q4 2022 was $66.0 million at Cullinan Therapeutics, down from $75.8 million in the prior quarter.
Over the last five years, Non-cash Items for CGEM hit a ceiling of $75.8 million in Q4 2021 and a floor of $66.0 million in Q4 2022.